@article{e9d553fdd9e24b08b749f2a4d412c41c,
title = "Chemogenomic library design strategies for precision oncology, applied to phenotypic profiling of glioblastoma patient cells",
author = "Paschalis Athanasiadis and Balaguru Ravikumar and Richard Elliott and Dawson, {John C.} and Carragher, {Neil O.} and Clemons, {Paul A.} and Timothy Johanssen and Daniel Ebner and Tero Aittokallio",
note = "Funding Information: The authors thank Dr. David Drewry (UNC Eshelman School of Pharmacy) for his critical review and useful comments on the manuscript draft, Dr. Jani Saarela (FIMM) for his help with the library construction and compound sourcing, and LifeArc for assistance in compound sourcing. We also acknowledge Professor Steven Pollard and Dr Gillian Morrison (University of Edinburgh) and the CRUK Glioma Cellular Genetic resource for the provision of patient-derived glioma stem cells. The authors acknowledge funding support from Cancer Research UK and the Brain Tumour Charity (grant REF: C42454/A28596 ), Norwegian Cancer Society (grant 216104 ), Helse S{\o}r-{\O}st (grant 2020026 ), Radium Hospital Foundation , and the Finnish Cancer Foundation . P.A.C. was supported in part by the National Cancer Institute's Cancer Target Discovery and Development ( CTDˆ2 ) Network ( U01CA217848 ). Funding Information: The authors thank Dr. David Drewry (UNC Eshelman School of Pharmacy) for his critical review and useful comments on the manuscript draft, Dr. Jani Saarela (FIMM) for his help with the library construction and compound sourcing, and LifeArc for assistance in compound sourcing. We also acknowledge Professor Steven Pollard and Dr Gillian Morrison (University of Edinburgh) and the CRUK Glioma Cellular Genetic resource for the provision of patient-derived glioma stem cells. The authors acknowledge funding support from Cancer Research UK and the Brain Tumour Charity (grant REF: C42454/A28596), Norwegian Cancer Society (grant 216104), Helse S{\o}r-{\O}st (grant 2020026), Radium Hospital Foundation, and the Finnish Cancer Foundation. P.A.C. was supported in part by the National Cancer Institute's Cancer Target Discovery and Development (CTDˆ2) Network (U01CA217848). Conceptualization, D.E. and T.A. Methodology, P.A. B.R. R.J.R.E. J.C.D. N.O.C. P.A.C. T.J. and D.E. Software, P.A. Formal Analysis, P.A. and T.A. Investigation, P.A. B.R. R.J.R.E. and J.C.D. Resources, N.O.C, P.A.C, D.E. Data Curation, P.A. and B.R. Writing – Original Draft, P.A. B.R. T.J. D.E. and T.A. Writing – Review & Editing, P.A. B.R. R.J.R.E. J.C.D. N.O.C. P.A.C. T.J. D.E. and T.A. Visualization, P.A. Supervision, D.E. N.O.C. and T.A. Funding Acquisition, N.O.C. P.A.C. D.E. and T.A. P.A.C. is an advisor to Pfizer, Inc. and Belharra Therapeutics. N.O.C is founder and shareholder of PhenoTherapeutics Ltd. Publisher Copyright: {\textcopyright} 2023 The Author(s)",
year = "2023",
month = jul,
day = "23",
doi = "10.1016/j.isci.2023.107209",
language = "English",
volume = "26",
pages = "107209",
journal = "iScience",
issn = "2589-0042",
publisher = "Cell Press",
number = "7",
}